High Drama for This High-Triglyceride Fighter


If Amarin investors' new plan is to ask companies on conference calls whether they have an interest in a making a deal, bravo. Amarin shares traded up nearly 10% intraday on the surprise disclosure during a shareholder call for Elan discussing other proposed purchases.

In this video, health-care analyst David Williamson discusses what this and the recent buyout of a competitor means for Amarin investors and what key catalyst is coming for the company before 2013 comes to a close.

Can Amarin beat the odds?
Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more simply click here now to claim your copy.

The article High Drama for This High-Triglyceride Fighter originally appeared on Fool.com.

David Williamson owns shares of Amarin. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.